Compare CSX Corporation (CSX) vs Iovance Biotherapeutics Inc. Common Stock (IOVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? CSX Corporation trades at $47.34 (market cap $86.70B), while Iovance Biotherapeutics Inc. Common Stock trades at $13.36 (market cap $5.85B). The key difference: CSX Corporation is far larger — about 14.8× Iovance Biotherapeutics Inc. Common Stock's market cap, and CSX Corporation pays a 1.2% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold CSX Corporation for 55 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| CSX | IOVA | |
|---|---|---|
Market Cap | $86.70B | $5.85B |
Volume | 6,811,485 | 14,517,176 |
Sector | Industrials | Health |
52-Week High | $53.21 | $14.82 |
52-Week Low | $33.68 | $1.81 |
Typical Hold Time | 55 Days | 0 Days |
Enterprise Value | $104.66B | $5.78B |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $47.34, down 0.34% today, with a bearish technical signal from moving averages. Recent earnings show mixed quarterly results, beating in Q1 and Q2 2026 but missing in Q4 2025. Revenue has declined from $14.9B in 2022 to $14.1B in 2025, though net income margin remains strong at 22.21%. Analyst consensus is bullish with a $51.00 price target, supported by institutional buying and positive news on dividend sustainability.
The outlook for CSX hinges on reversing revenue declines and executing on projected 2026 growth. Risks include competitive pressures and economic sensitivity, but strong profitability and analyst support offer upside. Investors should weigh valuation premiums against operational resilience in the freight sector.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →
